Q-omics provides the consensus-scored SNRNP70 profile across patient tissues and cancer cell-line models. SNRNP70 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNRNP70 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SNRNP70 protein abundance shows 32,144 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where SNRNP70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRNP70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRNP70 survival associations across molecular data types. SNRNP70 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRNP70 RNA expression–survival associations across cancer types. High SNRNP70 expression shows unfavorable associations in KIRC, ACC, SKCM, MESO and LIHC, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNRNP70 RNA expression.
This table summarizes SNRNP70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNRNP70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRNP70 shows higher tumor expression in COAD, KIRC, HNSC, LIHC, STAD and BLCA. The COAD box plot shows higher SNRNP70 RNA expression in tumor versus normal tissue (log2 FC = +1.171, t-test p < 0.001).
This table shows molecular features associated with SNRNP70 in patient tissues and cancer cell lines. In patient samples, SNRNP70 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRNP70 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
